カテゴリ： GlobalData, アメリカ, 企業調査

Ligand Pharmaceuticals Inc (LGND)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10033
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：128
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies and liver targeted pro-drug technologies to assist companies in securing prescription drug approvals. It provides a diversified portfolio of biotechnology and pharmaceutical products for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand also offers late-stage development, regulatory management and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc (LGND) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis 20
Venture Financing 21
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21
Partnerships 22
Ligand Pharma Enters into Agreement with venBio 22
Ligand Pharma Enters into Agreement with AiCuris 23
Symphogen Enters Into Agreement With Open Monoclonal Technology 24
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26
Open Monoclonal Expands Agreement with CNA Development 27
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 31
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 33
Licensing Agreements 34
WuXi Biologics Ireland Enters into Licensing Agreement with Ligand Pharma 34
Roivant Sciences Enters into Licensing Agreement with Ligand Pharma 35
Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 36
Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 37
Meridian Labs Enters into Licensing Agreement with Ligand Pharma 38
Amgen Enters into Licensing Agreement with Ligand Pharma 39
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 40
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 41
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 42
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 43
CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 44
Novartis Enters into Licensing Agreement with Ligand Pharma 45
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 46
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 47
TeneoBio Enters into Licensing Agreement with Ligand Pharma 48
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 49
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 50
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 51
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 52
RODES Enters into Licensing Agreement with Ligand Pharma 53
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 54
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 55
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 56
Sanofi Enters into Licensing Agreement with Ligand Pharma 57
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 58
Open Monoclonal Enters into Licensing Agreement with Celgene 59
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 60
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 61
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 62
Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 63
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 65
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 66
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 67
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 68
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 69
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 70
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 72
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 73
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 74
Ligand Pharma Amends Licensing Agreement with Retrophin 75
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 77
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 78
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 79
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 80
Open Monoclonal Enters into Licensing Agreement with Amgen 81
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 82
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 83
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 84
Ligand Pharma Enters Into Licencing Agreement With Merck 85
Equity Offering 86
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 86
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 87
Debt Offering 88
Ligand Pharma Raises USD750 Million in Private Placement of Notes Due 2023 88
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 89
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 91
Acquisition 92
Ligand Pharma Acquires Vernalis 92
Ligand Pharma Acquires Verrow Pharma 94
Ligand Pharma to Acquire Crystal Bioscience 95
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 96
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 97
Ligand Pharmaceuticals Inc – Key Competitors 98
Ligand Pharmaceuticals Inc – Key Employees 99
Ligand Pharmaceuticals Inc – Locations And Subsidiaries 100
Head Office 100
Other Locations & Subsidiaries 100
Recent Developments 102
Financial Announcements 102
Aug 06, 2018: Ligand reports second quarter 2018 financial results 102
May 08, 2018: Ligand Reports First Quarter 2018 Financial Results May 8, 2018 105
Feb 21, 2018: Ligand Reports Fourth Quarter and Full Year 2017 Financial Results 108
Nov 09, 2017: Ligand Reports Third Quarter 2017 Financial Results 111
Aug 07, 2017: Ligand Reports Second Quarter 2017 Financial Results 114
May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 117
Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 120
Corporate Communications 123
Aug 21, 2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors 123
Legal and Regulatory 124
Jul 27, 2018: Fr. Emmanuel Lemelson Responds to SEC Charges 124
Other Significant Developments 125
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies 125
Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 126
Appendix 128
Methodology 128
About GlobalData 128
Contact Us 128
Disclaimer 128

List of Tables
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis 20
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 21
Ligand Pharma Enters into Agreement with venBio 22
Ligand Pharma Enters into Agreement with AiCuris 23
Symphogen Enters Into Agreement With Open Monoclonal Technology 24
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 25
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 26
Open Monoclonal Expands Agreement with CNA Development 27
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 28
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 29
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 30
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 31
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 32
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 33
WuXi Biologics Ireland Enters into Licensing Agreement with Ligand Pharma 34
Roivant Sciences Enters into Licensing Agreement with Ligand Pharma 35
Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 36
Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 37
Meridian Labs Enters into Licensing Agreement with Ligand Pharma 38
Amgen Enters into Licensing Agreement with Ligand Pharma 39
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 40
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 41
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 42
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 43
CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 44
Novartis Enters into Licensing Agreement with Ligand Pharma 45
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 46
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 47
TeneoBio Enters into Licensing Agreement with Ligand Pharma 48
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 49
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 50
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 51
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 52
RODES Enters into Licensing Agreement with Ligand Pharma 53
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 54
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 55
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 56
Sanofi Enters into Licensing Agreement with Ligand Pharma 57
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 58
Open Monoclonal Enters into Licensing Agreement with Celgene 59
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 60
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 61
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 62
Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 63
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 65
Sage Therapeutics Amends Licensing Agreement with CyDex Pharma 66
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 67
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 68
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 69
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 70
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 72
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 73
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 74
Ligand Pharma Amends Licensing Agreement with Retrophin 75
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 77
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 78
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 79
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 80
Open Monoclonal Enters into Licensing Agreement with Amgen 81
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 82
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 83
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 84
Ligand Pharma Enters Into Licencing Agreement With Merck 85
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 86
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 87
Ligand Pharma Raises USD750 Million in Private Placement of Notes Due 2023 88
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 89
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 91
Ligand Pharma Acquires Vernalis 92
Ligand Pharma Acquires Verrow Pharma 94
Ligand Pharma to Acquire Crystal Bioscience 95
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 96
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 97
Ligand Pharmaceuticals Inc, Key Competitors 98
Ligand Pharmaceuticals Inc, Key Employees 99
Ligand Pharmaceuticals Inc, Subsidiaries 100

List of Figures
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Ligand Pharmaceuticals Inc (LGND)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Petro Matad Ltd (MATD)：石油・ガス：M&Aディール及び事業提携情報
    Summary Petro Matad Ltd (Petro Matad) is an oil and gas company that develops and operates oil and gas exploration properties. The company’s upstream oil and gas exploration asset base includes Block IV, Block XX, and Block V. Its Block XX is located in the far eastern part of Mongolia producing oil …
  • Graftys SA：製品パイプライン分析
    Summary Graftys SA (Graftys) is a medical device company that focuses on the development, manufacture and commercialization of synthetic bioactive orthopedic biomaterials. It provides a wide range of synthetic and bioresorbable bone graft substitutes and other cement products. The company’s products …
  • Duke Energy Indiana LLC：企業の発電所・SWOT分析2018
    Duke Energy Indiana LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • PT Bank Central Asia Tbk：企業の戦略・SWOT・財務情報
    PT Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Gritstone Oncology Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Gritstone Oncology Inc (Gritstone) is a cancer immunotherapy company that focuses on the development of personalized cancer therapeutics. The company primarily concentrates on identifying and deploying the therapeutic neo-antigens from individual patients’ tumors for the development of novel …
  • Vermilion Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Vermilion Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Vermilion Energy Inc (Vermilion) is an oil and gas company that offers exploration and production services. The company is an oil and gas producer in Alberta. It offers production programs focus …
  • Asplundh Tree Expert LLC：企業の戦略的SWOT分析
    Asplundh Tree Expert LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • GRI Bio Inc-製薬・医療分野：企業M&A・提携分析
    Summary GRI Bio Inc (GRI Bio) is a biotech company that develops and manufactures therapies for inflammatory diseases. The company develops Natural Killer T cell based therapies for the treatment of liver disease and autoimmune disoders. Its lead candidate GRI-0621, a novel oral therapeutic for live …
  • Akers Biosciences Inc (AKER)：企業の財務・戦略的SWOT分析
    Summary Akers Biosciences Inc (ABI) is a medical device company that develops, manufactures and supplies point-of-care screening and testing products. The company provides clinical diagnostics, safety diagnostics, and wellness products. ABI products include BreathScan alcohol detectors, CHUBE, METRO …
  • BE Semiconductor Industries N.V. (BESI)：企業の財務・戦略的SWOT分析
    BE Semiconductor Industries N.V. (BESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • First Bancorp. (FBP)：企業の財務・戦略的SWOT分析
    First Bancorp. (FBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • NovioSense BV-医療機器分野：企業M&A・提携分析
    Summary NovioSense BV (NovioSense) is a medical device company that develops a wireless technology platform for non-invasive monitoring of disease biomarkers. The company provides NovioSense, a glucose sensor to continuously monitor glucose levels in the tear fluid and sends a wireless signal to a h …
  • Nordic Investment Bank：電力：M&Aディール及び事業提携情報
    Summary Nordic Investment Bank (NIB) is a banking and financial service provider that offers loans and capital market solutions. The company offers loan products such as project and structured loans, corporate loans, municipality’s loans, environmental loans, sovereign loans, and other loans. It als …
  • Setpoint Medical Inc-医療機器分野：企業M&A・提携分析
    Summary SetPoint Medical Inc. (SetPoint Medical) is a biotechnology company that develops bioelectronic therapies for the treatment of inflammatory autoimmune diseases. The company employs a scientific platform, which is based on inflammatory reflex. The company’s bioelectronic medicine platform und …
  • PT Lotte Chemical Titan Tbk：企業の戦略・SWOT・財務情報
    PT Lotte Chemical Titan Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Lotte Chemical Titan Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Central Rand Gold Ltd：企業の戦略・SWOT・財務情報
    Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report Summary Central Rand Gold Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Kyowa Kirin Co Ltd (4151)：企業の財務・戦略的SWOT分析
    Kyowa Kirin Co Ltd (4151) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • SK Innovation Co Ltd (096770)：石油・ガス：M&Aディール及び事業提携情報
    Summary SK Innovation Co Ltd (SK Innovation) is an integrated energy and petrochemical company. It explores for and produces crude oil and natural gas; transportation of crude oil; and production of oil products such as gasoline and diesel. Through subsidiaries, the company carries out refining oper …
  • Yanchang Petroleum International Ltd (346)：企業の財務・戦略的SWOT分析
    Yanchang Petroleum International Ltd (346) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Humanwell Healthcare (Group) Co Ltd (600079)-医療機器分野：企業M&A・提携分析
    Summary Humanwell Healthcare (Group) Co Ltd (Humanwell), formerly Wuhan Humanwell Hi-Tech Industry Co Ltd is a pharmaceutical company that offers generic products. The company offers pharmaceutical, medical instrument and reproductive health care products and technologies. It provides anesthetics, b …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆